Replies to post #13268 on BioCurex, Inc.(fka BOCX)

[was Gyro]

Norad, thanks for posting that. From the article:
"According to the researcher who discovered the RECAF marker, Ricardo Moro-Vidal, M.D., CEO and president, the company is gearing up to begin a clinical trial with a leading institution to determine if a blood test can help radiologists better anticipate if a lesion is benign or malignant. In a malignant tumor, the levels of RECAF circulation within the blood increase. “If we can obtain 93 percent sensitivity and specificity, then we can potentially help reduce the number of false positives that lead to unnecessary breast biopsies,” he said."

Is it worth scouring the clinicaltrials.gov database for hints of something, or would the start of a trial be cause for a PR? Would it be subject to any of the issues that cause BOCX to want to be hush-hush about it?